Covid19, SARS-CoV Infection, Transplantation Infection
Conditions
Keywords
covid19, SARS-CoV Infection, transplantation
Brief summary
This project will provide novel data using a large cohort of more than 3000 transplanted patients. Risk and protective factors for SARS-CoV-2 infection and COVID-19 disease severity will be identified. The proportion of patients who develop antibodies after infection will be revealed. In this way the presence of these antibodies can be evaluated as a test for prior infection. Our study additionally will demonstrate how long these antibodies remain present and whether they are protective against a new infection.
Interventions
DIAGNOSTIC_TESTSARS-CoV-2 IgG
Collection of clinical variables, assessment of IgG antibodies for SARS-CoV-2, plasma collection for translational immunology studies
Sponsors
KU Leuven
Hasselt University
Ziekenhuis Oost-Limburg
Jessa Hospital
Universitaire Ziekenhuizen KU Leuven
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
No
Inclusion criteria
* all patients who underwent solid organ or hematopoietic cell transplantation at UZ Leuven and who give informed consent
Exclusion criteria
* age under 18 years
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Prevalence and risk-factors for SARS-CoV-2 infection | inclusion during 4 months | Prevalence and risk-factors for SARS-CoV-2 infection |
| Prevalence and risk-factors for COVID-19 | inclusion during 4 months | Prevalence and risk-factors for COVID-19 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Durability of IgG positivity | 12 months | Durability of IgG positivity/immunity |
Countries
Belgium
Contacts
Primary ContactJef Verbeek, MD, PhD
Backup ContactNatalie Van den Ende
Outcome results
None listed